Greenway reviews 2025, looks ahead to 2026

Executive Summary

• Greenway Greenhouse Cannabis Corp. reported its 2025 Year in Review, highlighting a 20% increase in total revenue and a 40% improvement in average selling price per gram compared to the previous year.
• The company successfully launched its international wholesale program, securing a strategic supply agreement with 4C Labs for the UK medical cannabis market and expanding presence in Europe and Australia.
• Greenway is positioned to increase production capacity by over 75% using existing, fully built-out cultivation space without requiring material incremental capital expenditures.

Key Details

• Financial Performance (2025):
  • Total revenue increased by 20% during the calendar year.
  • Average selling price per gram improved by over 40%, attributed to stronger demand and product quality.
• Operational Efficiency:
  • Maintained optimized output across 2.5 acres of active cultivation.
  • Achieved improved yields, tighter cost controls, and greater predictability in production planning through refinements in crop scheduling, strain selection, and facility utilization.
  • Management views these improvements as a durable step change in efficiency forming the backbone of the profitability strategy.
• International Expansion:
  • Entered multiple jurisdictions across Europe and Australia in its first full year of international market participation.
  • Announced a strategic supply agreement with 4C Labs in the United Kingdom, establishing a dedicated pathway for sales into the UK medical cannabis market.
  • Focus remains on building commercial relationships to supply growing demand in regulated global markets.
• Capacity and Growth Strategy:
  • Total production capabilities are expected to increase by more than 75% by bringing existing built-out capacity into production.
  • No material incremental capital expenditures are required for this expansion.
  • Management expects to scale output without negatively impacting per-gram production costs, thereby strengthening operating leverage.
• Corporate Action (Financing):
  • On December 31, 2025, the corporation issued 276,318 common shares arising from convertible debentures issued in October 2023.
  • Shares were issued at a deemed price of 19 cents.
  • Shares are subject to a hold period of four months and one day.
  • The issuance did not create any new control persons in the corporation.

Notable Quotes

• "Two thousand twenty-five was a year of meaningful progress for Greenway across several fronts... We delivered a 20-per-cent increase in total revenue during the calendar year, alongside an improvement in our average selling price per gram of over 40 per cent, reflecting both stronger demand and the quality of our product." — Jamie D'Alimonte, CEO
• "Looking ahead, the next phase of growth is centered on the utilization of our existing cultivation capacity... Based on our experience operating at scale, we believe we can increase output materially without negatively impacting our cost structure, positioning the company to drive higher revenues and improved profitability as we move forward." — Jamie D'Alimonte, CEO